Cox proportional hazard models were performed to determine independent influence factors of tumor-free survival

Cox proportional hazard models were performed to determine independent influence factors of tumor-free survival. group. Loss of 8p12-p23.2 was associated with high Imiquimod (Aldara) TNM stage tumors (P= 0.038) and was an unfavorable prognostic factor for tumor-free survival (P=0.045). A total of 133 differentially expressed proteins were identified in iTRAQ proteomics analysis, 69 (51.8%) of which mapped within identified RARs. The most common biological processes affected by HBV and AFB1 status in HCC tumorigenesis were detoxification and drug metabolism pathways, antigen processing and anti-apoptosis pathways. Expression of AKR1B10 was increased significantly in the HBV(+)/AFB1(+) and HBV(-)/AFB1(+) groups. A significant correlation between the expression of AKR1B10 mRNA and protein levels as well as AKR1B10 copy number was observered, which suggest that AKR1B10 may play a role in AFB1-related hepatocarcinogenesis. In summary, a number of genetic and gene expression alterations were found to be associated with HBV and AFB1- related HCC. The possible synergistic effects of HBV and AFB1 in hepatocarcinogenesis warrant further investigations. == Background == Hepatocellular carcinoma (HCC) is one of the most prevalent human cancers worldwide [1]. Epidemiological evidence suggests that several environmental factors are involved in the development of HCC [2,3]. In Japan and the United States, more than 70% of cases are related to chronic HCV contamination [4,5], while Imiquimod (Aldara) in Southern China and Plxnc1 sub-Saharan Africa, HCC is usually associated with high dietary exposure to aflatoxin B1 (AFB1) and hepatitis B virus (HBV) contamination and is the major causes of cancer mortality in these geographic areas [35]. Hepatocarcinogenesis is usually a complex process associated with the accumulation of genetic abnormalities that occur during initiation, promotion, and progression of the disease [6]. Both HBV contamination and AFB1 exposure can cause liver damage, and increase the probability of HCC [2,7]. They appear to play different roles in HCC development due to their various biological effects. AFB1 is the most prevalent and carcinogenic of the aflatoxins. When ingested, AFB1 is usually processed in the liver by the cytochromes P450 system to reactive epoxides which can damage DNA [8,9]. A number of studies have confirmed that more than 50% of HCC Imiquimod (Aldara) patients who have been exposed to AFB1 carry a mutation in codon 249 (AGGArgAGTSeror AGGArgAGCSer) of the p53 gene [911]. This hotspot mutation is considered a molecular marker reflecting AFB1-induced DNA damage that eventually results in HCC [1214]. Previous microarray chromosomal proteomic studies have identified genes or chromosomal regions that may be involved in hepatocarcinogenesis [1520]. These findings indicate that development of HCC is usually a complex polygene and multi-pathway process [21]. Genetic pathways associated with development of HBV-related HCC include RB1, methylation of p16INK4a, and amplification of Cyclin D1 [21]. In contrast, AFB1 alters the protein sequence of the tumor suppressor p53 gene which regulates the cell cycle and is important in conserving genome stability. Other ways by which AFB1 may act to promote HCC are poorly understood. HBV and AFB1 are also thought to influence the activity of comparable pathways to promote HCC. Currently, it is not clear if these two pathways can act synergistically to promote HCC via common or overlapping molecular mechanisms. It is important to understand how HBV and AFB1 affect HCC development in China where there is usually Imiquimod (Aldara) high exposure to both HBV and AFB1. In this study, we used array-based comparative genomic hybridization (aCGH) and Isobaric Tagging Reagent Quantitative (iTRAQ) proteomics to identify chromosomal regions and proteins/genes that are altered as a result of HBV and AFB1 exposure. The results of this study may provide additional markers and molecular targets for the diagnosis and treatment of these types of HCC. == Methods == This study enrolled 157 patients with HCC from the Tumor Hospital of Guangxi Medical University and First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Province, China. 32 of which were enrolled for array-based comparative genomic hybridization and isobaric tagging reagent quantitative analysis. The study was approved by the both hospitals institutional review boards and was performed according to the Declaration of Helsinki. All patients gave their informed consents. == Study patients == All patients (ages 23-75 years) had HCC and were unfavorable for HCV (as determined by serology and pathological analyses). All study patients were subjected to a rigorous screening procedure before they were categorized into subgroups. We defined HBV- related and AFB1- related status in this study.